Retraction notice to "30MO ORIENT-3: A randomized, open-label, phase III study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small cell lung cancer (sqNSCLC)": [Annals of Oncology Volume 31, Supplement 7, December 2020, Page S1428]

Y Shi; L Wu; X Yu; P Xing; J Zhou; A Wang; J Shi; Y Hu; Z Wang; G An; Y Fang; S Sun; C Zhou; C Wang; F Ye; X Li; J Wang; M Wang; Y Liu; Y Zhao

doi:10.1016/j.annonc.2021.01.009

Retraction notice to "30MO ORIENT-3: A randomized, open-label, phase III study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small cell lung cancer (sqNSCLC)": [Annals of Oncology Volume 31, Supplement 7, December 2020, Page S1428]

Ann Oncol. 2021 Apr;32(4):576. doi: 10.1016/j.annonc.2021.01.009.

Authors

Y Shi¹, L Wu², X Yu³, P Xing¹, J Zhou⁴, A Wang⁵, J Shi⁶, Y Hu⁷, Z Wang⁸, G An⁹, Y Fang¹⁰, S Sun¹¹, C Zhou¹², C Wang¹³, F Ye¹⁴, X Li¹⁵, J Wang¹⁶, M Wang¹⁷, Y Liu¹⁸, Y Zhao¹⁹

Affiliations

¹ Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
² Department II of Thoracic Medicine, Hunan Cancer Hospital, Changsha, China.
³ Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
⁴ Department of Respiratory Diseases, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
⁵ The Third Department of Chemotherapy, Weihai Municipal Hospital, Weihai, China.
⁶ Department of Oncology, Linyi Cancer Hospital, Linyi, China.
⁷ Medical Oncology, Chinese People's Liberation Army General Hospital, Beijing, China.
⁸ Department I of Thoracic Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
⁹ Department of Oncology, Beijing Chao-Yang Hospital, Beijing, China.
¹⁰ Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China.
¹¹ Department of Medical Oncology, Xuzhou Central Hospital, Xuzhou Medical University, Xuzhou, China.
¹² Department of Oncology, Shanghai Pulmonary Hospital, Shanghai, China.
¹³ Medical Oncology, Tianjin Cancer Hospital, Tianjin Medical University, Tianjin, China.
¹⁴ Cancer Hospital, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Teaching Hospital of Fujian Medical University, Department of Medical Oncology, Xiamen, China.
¹⁵ Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
¹⁶ Oncology Department, Affiliated Hospital of Jining Medical University, Jining, China.
¹⁷ Department of Respiratory Medicine, Peking Union Medical College Hospital, Beijing, China.
¹⁸ Department of Medical Oncology, Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
¹⁹ Department of Internal Medicine, Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.

PMID: 33736838
DOI: 10.1016/j.annonc.2021.01.009

Abstract

This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This article was retracted at the request of the authors. The authors of this abstract have advised that full agreement between authors and sponsors on publication of the abstract has not been reached and they are therefore unable to publish this data at present.

Publication types

Retraction of Publication